Core Viewpoint - Jihong Co., Ltd. reported a significant revenue growth of 29% and a net profit increase of 60% in the first three quarters of 2025, but underlying issues indicate potential risks and instability in performance [1][3][19]. Financial Performance - The company's revenue reached 5.039 billion yuan, with a net profit of 216 million yuan, driven primarily by the cross-border e-commerce and packaging businesses [3][19]. - The cross-border e-commerce segment is identified as the main growth engine, while the packaging business provides stable support, holding the largest market share in domestic paper packaging [3][19]. - Despite the impressive figures, the company has experienced significant profit volatility over the past four years, with net profit growth rates fluctuating between -59% and 88% [3][19]. Operational Challenges - The packaging business faces underutilization issues, with production utilization rates recorded at 63.2%, 55.7%, and 56.2% from 2022 to 2024, indicating idle production capacity [5][21]. - The company is navigating a dual pressure of share reduction and high pledge ratios among major shareholders, raising concerns about stock stability and shareholder confidence [6][22]. Financial Risks - Accounts receivable have surged to 623 million yuan, constituting 15.16% of total assets and 23.6% of net assets, indicating a significant amount of capital tied up with customers [8][23]. - Sales expenses have escalated to 1.756 billion yuan, a 42.26% increase year-on-year, marking the highest sales expense in a decade, which raises concerns about the efficiency of sales investments [9][12][27]. - The company has faced regulatory scrutiny for past violations related to related-party transactions, highlighting governance weaknesses [15][30].

Core Viewpoint - Zhejiang Haiseng Medical Equipment Co., Ltd. is set to go public on the Beijing Stock Exchange, with an IPO of up to 11.2941 million shares, primarily relying on a distribution model for revenue generation, which poses inherent risks due to high dealer turnover and profitability discrepancies between new and exiting dealers [2][3][4]. Revenue and Profitability - The company reported revenues of 268 million yuan, 306 million yuan, 304 million yuan, and 156 million yuan for the years 2022 to 2024 and the first half of 2025, with net profits of 70.11 million yuan, 78.04 million yuan, 70.92 million yuan, and 35.39 million yuan, indicating a revenue decline of 0.7% and a net profit decline of 9.12% in 2024 [3][4]. - The main revenue source is anesthesia equipment, which accounted for 47.92% to 52.6% of total revenue during the reporting period, with sales increasing from 130 million yuan to 160 million yuan [3][4]. Distribution Model - The distribution model is the core sales channel, contributing 90.43%, 89.57%, 85.06%, and 83.16% of total revenue from 2022 to the first half of 2025, with over 80% of revenue generated through distributors [4][5]. - The dealer structure shows significant volatility, with over 200 dealers entering and exiting annually, leading to concerns about the stability and profitability of the distribution network [5][6]. Dealer Profitability - There is a notable difference in gross profit margins between new and exiting dealers, with exiting dealers consistently showing higher margins, indicating that the company earns more profit from exiting dealers compared to new ones [7][8]. Sales and Expenses - Sales expenses over the past three and a half years totaled approximately 105 million yuan, nearly double the R&D expenses of about 56.42 million yuan, with a sales expense ratio rising to 10.63%, significantly higher than the industry average of 6.25% [9][10]. - Employee compensation constitutes over 60% of sales expenses, with the company having a higher proportion of sales personnel compared to peers, yet generating lower revenue per employee [9][10][11]. Comparison with Peers - Compared to peers like Weili Medical and Sanxin Medical, Haiseng Medical has a higher proportion of sales personnel and higher average salaries, but lower revenue generation per employee, highlighting inefficiencies in personnel utilization [10][12].